Evidence map›Paper›PMID 31558880›Full record

SynthesisWorld journal of gastroenterology2019

Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis.

Apostolos V Tsolakis, Athanasia Ragkousi, Miroslav Vujasinovic, Gregory Kaltsas, Kosmas Daskalakis

Abstract readComparative StudyMeta-AnalysisSystematic Review
In one paragraph

Synthesis in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Type 2 and type 3 gastric neuroendocrine tumors have high risk of lymph node metastasis: Systematic review and meta-analysis.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Unraveling the Mysteries of Autoimmune Gastritis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Review
  10. Modern Management of Gastric Neuroendocrine Neoplasms.Current treatment options in oncology · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Clinical characteristics and long-term prognosis of type 1 gastric neuroendocrine tumors in a large Japanese national cohort.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2023
    Article
  17. Review
  18. Current status of the role of endoscopy in evaluation and management of gastrointestinal and pancreatic neuroendocrine tumors.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Review
  19. Article
  20. [Management of Type 1 Gastric Neuroendocrine Tumors Less than 10 mm in Diameter].The Korean journal of helicobacter and upper gastrointestinal research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Apostolos V TsolakisDepartment of Oncology and Pathology, Karolinska Institute, Stockholm 17177, Sweden. apobtsol@hotmail.com.
Athanasia Ragkousi1 Department of Propaupedic Internal Medicine, Endocrine Oncology Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece.
Miroslav VujasinovicDepartment of Digestive Diseases, Karolinska University Hospital, Stockholm 14186, Sweden.
Gregory Kaltsas1 Department of Propaupedic Internal Medicine, Endocrine Oncology Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece.
Kosmas Daskalakis1 Department of Propaupedic Internal Medicine, Endocrine Oncology Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, the histopathological parameters predicting the risk of lymph node (LN) metastases and local recurrence, associated mortality and appropriateness of endoscopic or surgical resection in patients with gastric neuroendocrine neoplasms type 1 (GNENs1) have not been fully elucidated.

aimTo determine the rate of LN metastases and its impact in survival in patients with GNEN1 in relation to certain clinico-pathological parameters.

methodsThe PubMed, EMBASE, Cochrane Library, Web of Science and Scopus databases were searched through January 2019. The quality of the included studies and risk of bias were assessed using the Newcastle-Ottawa Scale (NOS) in accordance with the Cochrane guidelines. A random effects model and pooled odds ratios (OR) with 95%CI were applied for the quantitative meta-analysis.

resultsWe screened 2933 articles. Thirteen studies with 769 unique patients with GNEN1 were included. Overall, the rate of metastasis to locoregional LNs was 3.3% (25/769). The rate of LN metastases with a cut-off size of 10 mm was 15.3% for lesions > 10 mm (

conclusionThis meta-analysis confirms that tumor size ≥ 10 mm and invasion of the muscularis propria are linked to a higher risk of LN metastases in patients with GNEN1. Overall, the metastatic propensity of GNEN1 is low with favorable 5-year disease-specific survival rates reported; hence, no clear evidence of the prognostic value of LN positivity is available. Additionally, there is a lack of evidence supporting the prediction of local recurrence in GNEN1, even if surgery was more often a definitive treatment.

Indexed as

Disease-Free SurvivalEndoscopic Mucosal ResectionGastrectomyHumansLymphatic MetastasisLymph Node ExcisionNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeuroendocrine TumorsPatient SelectionPrognosisStomachStomach NeoplasmsSurvival RateTreatment OutcomeEndoscopyGastric neuroendocrine neoplasms type 1InvasionLymph node metastasisMeta-analysisSurgeryTumor size

Identifiers

PMID31558880
PMCPMC6761239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.